The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
12 01 2021
Historique:
received: 30 07 2020
accepted: 08 12 2020
entrez: 13 1 2021
pubmed: 14 1 2021
medline: 22 1 2021
Statut: epublish

Résumé

Smoldering myeloma (SMM) is associated with a high-risk of progression to myeloma (MM). We report the results of a study of 82 patients with both targeted sequencing that included a capture of the immunoglobulin and MYC regions. By comparing these results to newly diagnosed myeloma (MM) we show fewer NRAS and FAM46C mutations together with fewer adverse translocations, del(1p), del(14q), del(16q), and del(17p) in SMM consistent with their role as drivers of the transition to MM. KRAS mutations are associated with a shorter time to progression (HR 3.5 (1.5-8.1), p = 0.001). In an analysis of change in clonal structure over time we studied 53 samples from nine patients at multiple time points. Branching evolutionary patterns, novel mutations, biallelic hits in crucial tumour suppressor genes, and segmental copy number changes are key mechanisms underlying the transition to MM, which can precede progression and be used to guide early intervention strategies.

Identifiants

pubmed: 33436579
doi: 10.1038/s41467-020-20524-2
pii: 10.1038/s41467-020-20524-2
pmc: PMC7804406
doi:

Substances chimiques

Biomarkers, Tumor 0
KRAS protein, human 0
APOBEC Deaminases EC 3.5.4.5
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

293

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Références

Ann Oncol. 2015 Jan;26(1):64-70
pubmed: 25319062
Leukemia. 2016 Feb;30(2):417-22
pubmed: 26490489
Leukemia. 2012 Feb;26(2):349-55
pubmed: 21836613
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Nature. 2020 Feb;578(7793):94-101
pubmed: 32025018
BMC Bioinformatics. 2020 Apr 15;21(1):144
pubmed: 32293247
BMC Genomics. 2016 Nov 7;17(1):880
pubmed: 27821060
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):194-204
pubmed: 29222256
Blood. 2007 Oct 1;110(7):2586-92
pubmed: 17576818
Cancer Cell. 2007 Aug;12(2):115-30
pubmed: 17692804
Clin Cancer Res. 2020 May 15;26(10):2422-2432
pubmed: 31988198
J Clin Oncol. 2020 Jul 20;38(21):2380-2389
pubmed: 32442065
Nature. 2011 Aug 10;476(7359):163-9
pubmed: 21833082
Blood. 2018 Aug 9;132(6):587-597
pubmed: 29884741
Leukemia. 2013 Aug;27(8):1738-44
pubmed: 23515097
Leukemia. 2013 Apr;27(4):941-6
pubmed: 23183428
Eur J Haematol. 2016 Sep;97(3):303-9
pubmed: 26710662
Br J Haematol. 2003 Jun;121(5):749-57
pubmed: 12780789
Leukemia. 2020 Jan;34(1):322-326
pubmed: 31439946
Nat Commun. 2019 Aug 23;10(1):3835
pubmed: 31444325
Blood. 2013 Apr 25;121(17):3413-9
pubmed: 23435460
Nat Methods. 2014 Apr;11(4):396-8
pubmed: 24633410
J Clin Oncol. 2010 Mar 20;28(9):1606-10
pubmed: 20177023
Blood Cancer J. 2015 Oct 23;5:e364
pubmed: 26495861
Nat Commun. 2017 Aug 16;8(1):268
pubmed: 28814763
Haematologica. 2015 Sep;100(9):1214-21
pubmed: 26022710
Mayo Clin Proc. 2010 Mar;85(3):300
pubmed: 20194156
Br J Haematol. 2005 Sep;130(5):729-32
pubmed: 16115129
Leukemia. 2014 Feb;28(2):384-390
pubmed: 23817176
N Engl J Med. 2011 Aug 4;365(5):474-5
pubmed: 21812699
J Clin Oncol. 2015 Nov 20;33(33):3911-20
pubmed: 26282654
Cancer Res. 2017 Aug 15;77(16):4317-4327
pubmed: 28619709
Nat Commun. 2018 Aug 22;9(1):3363
pubmed: 30135448
Blood Cancer J. 2018 Jun 12;8(6):59
pubmed: 29895887

Auteurs

Eileen M Boyle (EM)

Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
INSERM 1052/CNRS 5286 Cancer Research Center of Lyon, Lyon, France.
Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.

Shayu Deshpande (S)

Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Ruslana Tytarenko (R)

Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Cody Ashby (C)

Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Yan Wang (Y)

Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Michael A Bauer (MA)

Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Sarah K Johnson (SK)

Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Christopher P Wardell (CP)

Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Sharmilan Thanendrarajan (S)

Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Maurizio Zangari (M)

Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Thierry Facon (T)

Service des maladies du sang. Hôpital Claude Huriez, Lille University Hospital, Lille, France.

Charles Dumontet (C)

INSERM 1052/CNRS 5286 Cancer Research Center of Lyon, Lyon, France.

Bart Barlogie (B)

Division of Hematology, The Mount Sinai Hospital, New York, NY, USA.

Arnaldo Arbini (A)

Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.

Even H Rustad (EH)

Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.

Francesco Maura (F)

Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Ola Landgren (O)

Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Fenghuang Zhan (F)

Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Frits van Rhee (F)

Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Carolina Schinke (C)

Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Faith E Davies (FE)

Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.

Gareth J Morgan (GJ)

Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA. Gareth.morgan@nyulangone.org.

Brian A Walker (BA)

Division of Hematology Oncology, Indiana University, Indianapolis, IN, USA. bw75@iu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH